Natl Toxicol Program Tech Rep Ser. 2012 May(572):1-188.
Methyl trans-styryl ketone is used as a synthetic flavoring agent and a fragrance additive in food and personal care products. Methyl trans-styryl ketone was nominated for study by the National Cancer Institute due to widespread human exposure as a flavoring and fragrance additive, positive results in the Ames/Salmonella assay and the mouse lymphoma L5178Y/tk+/- assay, and as a representative of the α,β-unsaturated ketone chemical class. Male and female F344/N rats and B6C3F1 mice received methyl trans-styryl ketone (98.6% pure) in feed for 3 months and dermally for 3 months or 2 years. Genetic toxicology studies were conducted in Salmonella typhimurium, Escherichia coli, and mouse peripheral blood erythrocytes. Two-year studies were conducted to provide data for assessment of possible toxicity due to exposure to methyl trans-styryl ketone. The dermal route was chosen since this is the route for highest human exposure and due to studies demonstrating systemic exposure following dermal application to methyl trans-styryl ketone. 3-MONTH FEED STUDY IN RATS Groups of 10 male and 10 female rats were fed diets containing 0%, 0.025%, 0.05%, 0.1%, 0.2%, or 0.4% methyl trans-styryl ketone (equivalent to average daily doses of approximately 18, 36, 72, 145, or 290 mg methyl trans-styryl ketone/kg body weight to males and 19, 38, 77, 150, or 300 mg/kg to females) for 14 weeks. Groups of 10 male and 10 female clinical pathology rats were fed the same concentrations for 24 days. All core study rats survived to the end of the study. Final mean body weights of males and females receiving 0.4% and mean body weight gains of males receiving 0.4% were significantly less than those of the controls. Feed consumption by exposed groups was similar to that by the controls. Clinical findings included diarrhea and hyperactivity in males and females. Results of sperm motility and vaginal cytology evaluations indicated methyl trans-styryl ketone is unlikely to be a reproductive toxicant in male rats; however, it exhibits potential for reproductive toxicity in female rats based upon an increased probability of extended diestrus at the highest exposure concentration. In all exposed groups of males, there were treatment-related increased incidences of goblet cell hyperplasia of the respiratory epithelium of the nose and nephropathy of the kidney. In females, there was an increased incidence of goblet cell hyperplasia of the respiratory epithelium of the nose in the group receiving 0.4%. 3-MONTH FEED STUDY IN MICE: Groups of 10 male and 10 female mice were fed diets containing 0%, 0.025%, 0.05%, 0.1%, 0.2%, or 0.4% methyl trans-styryl ketone (equivalent to average daily doses of approximately 55, 110, 220, 400, or 750 mg/kg to males and 50, 100, 200, 350, or 600 mg/kg to females) for 14 weeks. One male receiving 0.2% and one control female died before the end of the study. Mean body weights of males and females receiving 0.4% were significantly less than those of the controls. Feed consumption by exposed groups was similar to that by the controls. Hyperactivity in both sexes was the only clinical finding. Results of sperm motility and vaginal cytology evaluations indicated methyl trans-styryl ketone is unlikely to be a reproductive toxicant in male mice; however, it exhibits potential for reproductive toxicity in female mice based upon an increased probability of extended diestrus at the lowest and the highest exposure concentrations. There were significantly increased incidences of olfactory epithelial atrophy of the nose in males and females receiving 0.4%. 3-MONTH DERMAL STUDY IN RATS: Groups of 10 male and 10 female rats were dermally administered 0, 22, 44, 87.5, 175, or 350 mg methyl trans-styryl ketone/kg body weight in 95% ethanol, 5 days per week for 14 weeks. Groups of 10 male and 10 female clinical pathology rats were administered the same doses for 23 days. All rats survived to the end of the study. Mean body weights of 175 and 350 mg/kg males were significantly less than that of the vehicle controls. Clinical findings in groups administered 175 or 350 mg/kg included dermal irritation, thickened skin, and ulceration at the site of application. Results of sperm motility and vaginal cytology evaluations indicated methyl trans-styryl ketone is unlikely to be a reproductive toxicant in male or female rats at the doses used in this study. Histologically, there were significantly increased incidences of epidermal hyperplasia, hyperkeratosis, chronic active inflammation, epidermal necrosis, and sebaceous gland hypertrophy in the skin at the site of application in males and/or females. There were significantly increased incidences of goblet cell hyperplasia of the nose in 350 mg/kg males and 22, 175, and 350 mg/kg females. 3-MONTH DERMAL STUDY IN MICE Groups of 10 male and 10 female mice were dermally administered 0, 87.5, 175, 350, 700, or 1,400 mg methyl trans-styryl ketone/kg body weight in 95% ethanol, 5 days per week for 13 weeks. All mice in the 700 and 1,400 mg/kg groups were sacrificed moribund before the end of the study. The final mean body weights of surviving groups of dosed males and females were similar to those of the vehicle controls; however, the mean body weight gains of the 175 mg/kg groups were significantly less than those of the vehicle controls. Clinical findings at the site of application included dermal irritation in 350 mg/kg males and crust formation in all 700 and 1,400 mg/kg mice except one female. Results of sperm motility and vaginal cytology evaluations indicated methyl trans-styryl ketone is unlikely to be a reproductive toxicant in male or female mice at the doses used in this study. There were treatment-related increased incidences of epidermal hyperplasia, hyperkeratosis, chronic active inflammation, epidermal necrosis, sebaceous gland hypertrophy, and hair follicle hyperplasia in the skin at the site of application in males and females. There were increased incidences of olfactory epithelial atrophy of the nose in groups of males and females administered 350 mg/kg or greater. 2-YEAR DERMAL STUDY IN RATS: Groups of 50 male and 50 female rats were dermally administered 0, 10, 30, or 90 mg methyl trans-styryl ketone/kg body weight in 95% ethanol, 5 days per week for 105 weeks. Survival of all dosed groups was similar to that of the vehicle controls. Mean body weights of dosed groups were within 10% of those of the vehicle control groups throughout the study. In the skin at the site of application, there were increased incidences of epidermal hyperplasia and hyperkeratosis in males and females administered 30 or 90 mg/kg. 2-YEAR DERMAL STUDY IN MICE: Groups of 50 male and 50 female mice were dermally administered 0, 10, 30, or 90 mg methyl trans-styryl ketone/kg body weight in 95% ethanol, 5 days per week for 105 weeks. Survival of all dosed groups was similar to that of the vehicle controls. Mean body weights of dosed groups were within 10% of those of the vehicle control groups throughout the study. In the skin at the site of application in males and females, there were treatment-related increased incidences of epidermal hyperplasia, hyperkeratosis, chronic inflammation, and melanocyte hyperplasia.
Methyl trans-styryl ketone was mutagenic in Salmonella typhimurium strain TA100 when testing was conducted in the presence of rat liver microsomes (S9). No mutagenic activity was seen with methyl trans-styryl ketone in strain TA98 with or without S9 or in Escherichia coli strain WP2 uvrA/pKM101 in the absence of S9. With S9, inconsistent responses were seen in the E. coli tester strain. No increases in the frequencies of micronucleated normochromatic erythrocytes were seen in peripheral blood samples from male or female mice administered methyl trans-styryl ketone for 3 months via dosed feed or dermal application.
Under the conditions of these 2-year dermal studies, there was no evidence of carcinogenic activity of methyl trans-styryl ketone in male or female F344/N rats or in male or female B6C3F1 mice administered 10, 30, or 90 mg/kg. Administration of methyl trans-styryl ketone resulted in nonneoplastic lesions of the skin at the site of application in male and female rats and mice. Synonyms: Acetocinnamone; benzalacetone; benzylideneacetone; methyl 2-phenylvinyl ketone; methyl styryl ketone; methyl β-styryl ketone; MSK; 4-phenyl-3-butene-2-one; 4-phenylbutenone; 2-phenylvinyl methyl ketone; styryl methyl ketone Systematic name: (3E)-4-Phenylbut-3-en-2-one.
反式甲基苯乙烯基酮用作食品和个人护理产品中的合成调味剂和香料添加剂。由于作为调味剂和香料添加剂在人群中广泛存在暴露情况、在艾姆斯/沙门氏菌试验和小鼠淋巴瘤L5178Y/tk+/-试验中呈阳性结果,以及作为α,β-不饱和酮化学类别的代表,反式甲基苯乙烯基酮被美国国家癌症研究所指定进行研究。雄性和雌性F344/N大鼠以及B6C3F1小鼠经口摄入反式甲基苯乙烯基酮(纯度98.6%)3个月,并经皮给予3个月或2年。在鼠伤寒沙门氏菌、大肠杆菌和小鼠外周血红细胞中进行了遗传毒理学研究。开展了为期两年的研究,以提供有关因接触反式甲基苯乙烯基酮可能产生的毒性评估数据。选择经皮给药途径是因为这是人类暴露最高的途径,并且有研究表明经皮应用反式甲基苯乙烯基酮后会出现全身暴露情况。
大鼠经口3个月研究:将10只雄性和10只雌性大鼠分为几组,分别喂食含0%、0.025%、0.05%、0.1%、0.2%或0.4%反式甲基苯乙烯基酮的饲料(相当于雄性大鼠平均每日剂量约为18、36、72、145或290毫克反式甲基苯乙烯基酮/千克体重,雌性大鼠为19、38、77、150或300毫克/千克体重),持续14周。将10只雄性和10只雌性临床病理学大鼠分为几组,喂食相同浓度的饲料24天。所有核心研究大鼠均存活至研究结束。接受0.4%反式甲基苯乙烯基酮的雄性和雌性大鼠的最终平均体重以及接受0.4%反式甲基苯乙烯基酮的雄性大鼠的平均体重增加量均显著低于对照组。暴露组的饲料消耗量与对照组相似。临床发现包括雄性和雌性大鼠出现腹泻和多动。精子活力和阴道细胞学评估结果表明,反式甲基苯乙烯基酮不太可能对雄性大鼠具有生殖毒性;然而,基于在最高暴露浓度下延长动情间期的概率增加,它对雌性大鼠表现出潜在的生殖毒性。在所有暴露的雄性大鼠组中,鼻呼吸上皮杯状细胞增生和肾病的发生率与治疗相关增加。在接受0.4%反式甲基苯乙烯基酮的雌性大鼠组中,鼻呼吸上皮杯状细胞增生的发生率增加。
小鼠经口3个月研究:将10只雄性和10只雌性小鼠分为几组,分别喂食含0%、0.025%、0.05%、0.1%、0.2%或0.4%反式甲基苯乙烯基酮的饲料(相当于雄性大鼠平均每日剂量约为55、110、220、400或750毫克/千克体重,雌性大鼠为50、100、200、350或600毫克/千克体重),持续14周。一只接受0.2%反式甲基苯乙烯基酮的雄性小鼠和一只对照雌性小鼠在研究结束前死亡。接受0.4%反式甲基苯乙烯基酮的雄性和雌性小鼠的平均体重显著低于对照组。暴露组的饲料消耗量与对照组相似。两性多动是唯一的临床发现。精子活力和阴道细胞学评估结果表明,反式甲基苯乙烯基酮不太可能对雄性小鼠具有生殖毒性;然而,基于在最低和最高暴露浓度下延长动情间期的概率增加,它对雌性小鼠表现出潜在的生殖毒性。接受0.4%反式甲基苯乙烯基酮的雄性和雌性小鼠中,鼻嗅上皮萎缩的发生率显著增加。
大鼠经皮3个月研究:将10只雄性和10只雌性大鼠分为几组,每周5天,连续14周经皮给予0、22、44、87.5、175或350毫克反式甲基苯乙烯基酮/千克体重,溶媒为95%乙醇。将10只雄性和10只雌性临床病理学大鼠分为几组,给予相同剂量23天。所有大鼠均存活至研究结束。175和350毫克/千克体重组的雄性大鼠平均体重显著低于溶媒对照组。给予175或350毫克/千克体重组的临床发现包括皮肤刺激、皮肤增厚以及给药部位溃疡。精子活力和阴道细胞学评估结果表明,在本研究中使用的剂量下,反式甲基苯乙烯基酮不太可能对雄性或雌性大鼠具有生殖毒性。组织学检查显示,雄性和/或雌性大鼠给药部位皮肤的表皮增生、角化过度、慢性活动性炎症、表皮坏死和皮脂腺肥大的发生率显著增加。350毫克/千克体重组的雄性大鼠以及22、175和350毫克/千克体重组的雌性大鼠中,鼻杯状细胞增生的发生率显著增加。
小鼠经皮3个月研究:将10只雄性和-10只雌性小鼠分为几组,每周5天,连续13周经皮给予0、87.5、175、350、700或1400毫克反式甲基苯乙烯基酮/千克体重,溶媒为95%乙醇。700和1400毫克/千克体重组的所有小鼠在研究结束前濒死时被处死。给药的雄性和雌性存活组的最终平均体重与溶媒对照组相似;然而,175毫克/千克体重组的平均体重增加量显著低于溶媒对照组。给药部位的临床发现包括350毫克/千克体重组的雄性小鼠出现皮肤刺激,以及所有700和1400毫克/千克体重组的小鼠(除一只雌性外)出现结痂。精子活力和阴道细胞学评估结果表明,在本研究中使用的剂量下,反式甲基苯乙烯基酮不太可能对雄性或雌性小鼠具有生殖毒性。雄性和雌性小鼠给药部位皮肤的表皮增生、角化过度、慢性活动性炎症、表皮坏死、皮脂腺肥大和毛囊增生的发生率与治疗相关增加。给予350毫克/千克体重或更高剂量的雄性和雌性小鼠组中,鼻嗅上皮萎缩的发生率增加。
大鼠经皮2年研究:将50只雄性和50只雌性大鼠分为几组,每周5天,连续105周经皮给予0、10、30或90毫克反式甲基苯乙烯基酮/千克体重,溶媒为95%乙醇。所有给药组的存活率与溶媒对照组相似。在整个研究过程中,给药组的平均体重与溶媒对照组的平均体重相差在10%以内。在给药部位的皮肤中,给予30或90毫克/千克体重的雄性和雌性大鼠的表皮增生和角化过度的发生率增加。
小鼠经皮2年研究:将50只雄性和50只雌性小鼠分为几组,每周5天,连续105周经皮给予0、10、30或90毫克反式甲基苯乙烯基酮/千克体重,溶媒为95%乙醇。所有给药组的存活率与溶媒对照组相似。在整个研究过程中,给药组的平均体重与溶媒对照组的平均体重相差在10%以内。在雄性和雌性小鼠给药部位的皮肤中,与治疗相关的表皮增生、角化过度、慢性炎症和黑素细胞增生的发生率增加。
在存在大鼠肝微粒体(S9)的情况下进行测试时,反式甲基苯乙烯基酮在鼠伤寒沙门氏菌TA100菌株中具有致突变性。在有或无S9的情况下,反式甲基苯乙烯基酮在TA98菌株中均未观察到致突变活性,在无S9的情况下,在大肠杆菌WP2 uvrA/pKM101菌株中也未观察到致突变活性。在有S9的情况下,在大肠杆菌测试菌株中观察到不一致的反应。在通过喂食或经皮给药给予反式甲基苯乙烯基酮3个月的雄性或雌性小鼠的外周血样本中,未观察到微核正染红细胞频率增加。
在这两项为期两年的经皮研究条件下,没有证据表明给予10、30或90毫克/千克体重的反式甲基苯乙烯基酮对雄性或雌性F344/N大鼠或雄性或雌性B6C3F1小鼠具有致癌活性。给予反式甲基苯乙烯基酮导致雄性和雌性大鼠及小鼠给药部位皮肤出现非肿瘤性病变。
乙酰肉桂酮;苯亚甲基丙酮;苄叉丙酮;甲基2-苯基乙烯基酮;甲基苯乙烯基酮;甲基β-苯乙烯基酮;MSK;4-苯基-3-丁烯-₂-酮;4-苯基丁烯酮;2-苯基乙烯基甲基酮;苯乙烯基甲基酮
(3E)-4-苯基丁-3-烯-2-酮